托珠单抗在术后骨髓单核细胞性类白血病反应管理中的应用。
Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction.
作者信息
Melody Megan, Butts Emily, Menke David, Landolfo Kevin, Oken Keith, Sher Taimur, Khurana Sharad
机构信息
Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, United States.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, United States.
出版信息
Leuk Res Rep. 2020 Nov 4;14:100228. doi: 10.1016/j.lrr.2020.100228. eCollection 2020.
Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post-operative myelomonocytic leukemoid reaction (PO-MMLR), effectively treated with tocilizumab. Although, further studies are needed to validate the effectiveness of tocilizumab in management of PO-MMLR, this case serves to provide a new management approach in treatment of this rare but lethal syndrome with no standardized treatment options.
白细胞介素6受体（IL6R）抑制剂托珠单抗已有效用于接受嵌合抗原受体T细胞疗法患者的细胞因子释放综合征治疗。本文介绍了一名慢性粒单核细胞白血病（CMML）患者，该患者发生了类固醇难治性术后粒单核细胞白血病样反应（PO-MMLR），使用托珠单抗治疗有效。尽管需要进一步研究来验证托珠单抗在治疗PO-MMLR中的有效性，但该病例为治疗这种罕见但致命且尚无标准化治疗方案的综合征提供了一种新的管理方法。
Zotero 插件